PMR Maintains Positive Outlook On Liquid Biopsy Products Market Growth

Liquid Biopsy Products Market
Liquid Biopsy Products Market

The global liquid biopsy products market is expected to register remarkable CAGR during the forecast period from 2016 to 2026. The less invasive biopsies are able to address significant challenges associated with conventional biopsies such as, high level of invasiveness, incompleteness of cancer information acquired, associated post-biopsy serious medical complications and subsequent cost inclusions. The global liquid biopsy products market has gained considerable traction in the past decade owing to several clinical research studies such as the ones on circulating tumor cells and cell-free tumor DNA. Thus, the number of ongoing clinical trials that are due will be completed during 2016-2026. After successful completion the commercialization of these liquid biopsy products, assays and tests will provide the market a significant boost through 2026 in terms of revenue.

In 2016, largest share of the global market is expected to be accounted by North America due to factors such as easy accessibility and high adoption of advanced diagnostic technologies. The technologies like PCR and NGS play an important role. Also, among healthcare professionals, increasing prevalence of cancer in the U.S. and Canada and continuous technological advancements in liquid biopsy is remarkable. Asia-Pacific liquid biopsy products market is however estimated to witness the highest growth during the forecast period owing to the increasing focus of market players on this region.

Request to View Sample of Research Report @ 

Some players operating in liquid biopsy products market are Biocept Inc., Myriad Genetics, Qiagen, Roche, Bio-Rad Laboratories Inc., Trovagene Inc., Guardant Health, Inc., Janssen Diagnostics, LLC, Fraunhofer – Gesellschaft, and MDxHealth S.A., Genomic Health to name a few.

Leave a Reply